Foundayo vs Wegovy vs Zepbound: 2026 Head-to-Head

This three-way comparison is part of Weight Loss Rankings' living editorial database — 100+ research articles and 158+ clinically-reviewed GLP-1 telehealth providers, sourced only from primary FDA labels and peer-reviewed PubMed literature.

On April 1, 2026, the FDA approved Foundayo (orforglipron), the first oral non-peptide GLP-1 receptor agonist for chronic weight management^[1]. It enters a market dominated by two injectable heavyweights: Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide 15 mg). The three drugs differ on every dimension that matters to a patient — effect size, delivery, price, titration, side effects, and access. This is the head-to-head with the trial data, the 2026 pricing, and the case for picking each.

The 30-second answer

• Want the biggest weight loss? Zepbound (tirzepatide 15 mg) — 20.9% mean at 72 weeks in SURMOUNT-1^[3].
• Want the cheapest drug if you have commercial insurance? Foundayo with the Lilly Savings Card — $25/month^[1].
• Want the cheapest brand-name injectable self-pay? Wegovy NovoCare at $199/month all-dose subscription^[7].
• Hate needles? Foundayo (oral pill, no injections, no refrigeration).
• Have type 2 diabetes too? Zepbound (tirzepatide is also Mounjaro for diabetes — proven A1C reduction).

The drugs at a glance

Three FDA-approved weight management GLP-1 receptor agonists, three different mechanisms and delivery formats. For the full reference list of every FDA-approved and investigational GLP-1 medication on the US market in 2026 — including the seven T2D-only GLP-1s, the three FDA-approved generics (Hikma, Teva, Amneal), and the eight-drug investigational pipeline — see our GLP-1 medication list 2026 full reference.

• Wegovy (semaglutide 2.4 mg) — once-weekly subcutaneous injection. Pure GLP-1 receptor agonist. Approved for chronic weight management since June 2021. Manufacturer: Novo Nordisk.
• Zepbound (tirzepatide 15 mg) — once-weekly subcutaneous injection. Dual GLP-1 + GIP (glucose-dependent insulinotropic polypeptide) receptor agonist. Approved for chronic weight management since November 2023. Manufacturer: Eli Lilly.
• Foundayo (orforglipron) — daily oral tablet. Non-peptide small-molecule GLP-1 receptor agonist (chemically very different from semaglutide and tirzepatide, which are peptide drugs). Approved for chronic weight management on April 1, 2026^[1]. Manufacturer: Eli Lilly.

Effect size — the trial data, head to head

All three drugs were tested in 68-72 week phase 3 obesity trials with similar designs (placebo-controlled, mean BMI ~37, primary endpoint = percent change in body weight). The published mean weight loss results:

• Wegovy (STEP-1)^[2] — −14.9% mean weight loss at week 68 vs −2.4% on placebo. n=1,961. About 86% of patients lost ≥5% body weight.
• Zepbound (SURMOUNT-1)^[3] — −20.9% mean at week 72 vs −3.1% placebo. n=2,539. About 91% lost ≥5%. (5 mg dose: −16.0%; 10 mg: −19.5%; 15 mg: −20.9%.)
• Foundayo at the FDA-labeled maximum dose of 17.2 mg in adults without type 2 diabetes — −11.1% mean weight loss (about −24.9 lbs) at 72 weeks per the FDA-approved prescribing information^[11]. ATTAIN-1, the registration trial, excluded adults with type 2 diabetes; the T2D population for orforglipron is being evaluated separately under the ATTAIN-2 / ACHIEVE program.

Important note on Foundayo numbers. The ATTAIN-1 phase 3 trial^[10] tested 6, 12, and 36 mg orforglipron arms — not the FDA-approved 17.2 mg labeled maximum. The 36 mg trial arm produced −11.2% on the treatment-regimen (ITT) estimand and −12.4% on the efficacy (completers) estimand. Some third-party marketing pages quote the 36 mg trial result without disclosing it is a supra-labeled dose; the labeled-dose figure (−11.1% at 17.2 mg) is what consumers should expect when prescribed Foundayo.

Two important caveats on direct comparison:

1. These are not head-to-head trials. STEP-1, SURMOUNT-1, and ATTAIN-1 each compared their drug against placebo, not against each other. The only published direct head-to-head between any two of these drugs is SURPASS-2^[9], which compared tirzepatide vs semaglutide in type 2 diabetes (not obesity) and showed tirzepatide's superiority on both A1C and weight loss.
2. Patient populations differ slightly across trials. STEP-1 and ATTAIN-1 enrolled patients with mean BMI ~38; SURMOUNT-1 enrolled patients with mean BMI ~38 as well, but with different prior weight loss attempts and different regional distributions. Effect sizes are comparable but not perfectly interchangeable.

Cost — the 2026 cash-pay landscape

This is where Foundayo changes the market most dramatically. Pricing as of April 2026:

Wegovy^[7]

• $499/month standard NovoCare direct-pay (any dose strength)
• $199/month all-dose subscription (cash pay only, no insurance, includes free shipping)
• With commercial insurance covering Wegovy: typically $25-$100/month copay after PA approval

Zepbound^[8]

• $299/month for the 2.5 mg starter dose via LillyDirect Self Pay (price drop December 1, 2025)
• $399/month for the 5 mg dose
• $449/month for the 7.5 mg and higher doses
• With commercial insurance covering Zepbound: typically $25-$100/month copay

Foundayo^[1]

• $25/month with the Lilly Savings Card for commercially insured patients (not Medicare or Medicaid)
• $149/month list price for cash-pay patients without insurance
• No syringes, no needles, no cold chain, no shipping cost structure (it's a pill — distributed through standard pharmacy channels)

The Foundayo $25/month savings card price is the cheapest legal path to a brand-name FDA-approved GLP-1 in 2026 by a wide margin. It is roughly 1/20th the cost of Wegovy NovoCare and 1/18th the cost of Zepbound at the maintenance dose. The catch: the savings card requires commercial insurance, not Medicare or Medicaid.

Delivery — pill vs injection

Wegovy and Zepbound are subcutaneous injections delivered by single-use auto-injector pens. You inject once a week, you rotate sites, you store the pens in the refrigerator, and you travel with a cooler if you fly. See our step-by-step injection technique guide for the operational details.

Foundayo is a daily oral tablet. No injections, no needle disposal, no refrigeration, no cold chain, no airport pat-down conversation about medical-device exemptions. Per the FDA-approved prescribing information, Foundayo can be taken any time of day, with or without food, and with no water restrictions^[11]. This is the central dosing-experience differentiator from Rybelsus (oral semaglutide), which is a peptide that must be taken on an empty stomach with no more than 4 ounces of water followed by a 30-minute wait before anything else by mouth. Because orforglipron is a non-peptide small molecule, it survives stomach acid and digestion without an absorption enhancer — so the Foundayo label carries none of Rybelsus's food, water, or timing restrictions. For the full side-by-side comparison of every FDA-approved oral GLP-1 — Rybelsus vs Foundayo, plus the regulatory status of Novo Nordisk's high-dose oral semaglutide for weight management — see our GLP-1 pills 2026 comparison.

See our (forthcoming) how to take Foundayo guide for the full daily protocol, food restrictions, and missed-dose rules.

Titration schedule

• Wegovy — 5 dose steps: 0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg, with at least 4 weeks between each dose increase per the Wegovy label. Total escalation time to maintenance: ~16-20 weeks.
• Zepbound — 6 dose steps: 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg, with at least 4 weeks between each dose increase per the Zepbound label. Total: ~20-24 weeks. Lower maintenance doses (5 mg or 10 mg) are also FDA-labeled and produce meaningful weight loss, so not every patient escalates to 15 mg.
• Foundayo — 6 dose steps per the FDA label: 0.8 mg → 2.5 mg → 5.5 mg → 9 mg → 14.5 mg → 17.2 mg, with at least 30 days between each dose increase per the Foundayo prescribing information^[11]. Total: roughly 6 months to the labeled maximum dose. For a calendar-anchored Days 1-90 walkthrough of what each Foundayo dose feels like in practice, see our Foundayo week-by-week titration guide.

All three follow the same general principle of slow upward titration to manage GI side effects. Foundayo's steps are smaller in fractional terms, which may help tolerance.

Side effect profile — the trial-reported rates

All three drugs share the GLP-1 class side effects: nausea, vomiting, diarrhea, constipation, dyspepsia. The trial-reported rates at the maintenance dose:

• Wegovy (STEP-1)^[2] — 44.2% nausea, 24.8% vomiting, 31.5% diarrhea, 23.4% constipation. ~4.5% discontinued for GI side effects.
• Zepbound (SURMOUNT-1)^[3] at the 15 mg dose — approximately 29.0% nausea, 12.2% vomiting, 21.2% diarrhea, 11.7% constipation (SURMOUNT-1 supplementary tables). ~4.3% discontinued for GI.
• Foundayo (ATTAIN-1) — preliminary data suggest a lower nausea rate than Wegovy, similar to or slightly above tirzepatide. The full AE table will be in the published manuscript and the FDA label.

See our GLP-1 nausea management guide for the practical strategies that apply across all three drugs.

Drug interaction profile

All three carry the same boxed warning for medullary thyroid carcinoma based on rodent studies (see our cancer and MTC article), and all three are contraindicated in MEN2 and personal or family MTC history. The injectable GLP-1s and Foundayo differ on one important interaction:

• Wegovy and Zepbound — no specific oral contraceptive warning. PK studies have not shown clinically meaningful reduction in OCP bioavailability for the injectables.
• Foundayo — Section 7.1 of the label specifically recommends a non-oral contraceptive method (or barrier backup) for 30 days after starting and 30 days after each dose increase. This is because Foundayo is itself an oral drug and the gastric-emptying-and- absorption interaction is more direct.
• Foundayo + strong CYP3A4 inhibitors — when co-administered with a strong CYP3A4 inhibitor (e.g., clarithromycin, itraconazole, ketoconazole, or ritonavir-boosted antivirals), the Foundayo label caps the maximum daily dose at 9 mg once daily^[11]. This is a labeled drug-drug interaction warning unique to Foundayo among the three weight-loss GLP-1s.

See our GLP-1 drug interaction checker for the full per-drug interaction database.

Pharmacokinetics and washout

• Wegovy — semaglutide t½ ~7 days. Steady state in 4-5 weeks. Pre-pregnancy washout: 2 months (per the label).
• Zepbound — tirzepatide t½ ~5 days. Steady state in 3-4 weeks. Same 2-month pre-pregnancy washout in clinical practice.
• Foundayo — orforglipron t½ 29-49 hours per the FDA label^[11]. Steady state in approximately 5-10 days (roughly 4-5 half-lives). Much shorter washout than the injectables — useful for pre-procedure hold and pre-pregnancy planning.

Use our GLP-1 washout calculator to see the residual concentration timeline for any of the three drugs.

The case for each drug

Pick Wegovy if...

• You have insurance that covers it on formulary, OR
• You want the cheapest brand-name injectable cash-pay option ($199/month NovoCare all-dose), OR
• You have cardiovascular disease (the SELECT trial showed a 20% reduction in cardiovascular events on semaglutide 2.4 mg, which gave Wegovy a labeled CV benefit indication that Zepbound and Foundayo do not yet have)

Pick Zepbound if...

• You want the largest expected weight loss (20.9% mean in SURMOUNT-1 vs 14.9% Wegovy and 11.1% Foundayo at the 17.2 mg labeled max dose)
• You have type 2 diabetes (tirzepatide also exists as Mounjaro for diabetes — same drug, same manufacturer, different label)
• You have obstructive sleep apnea (the SURMOUNT-OSA trial showed tirzepatide reduced sleep apnea severity, and Zepbound has a labeled OSA indication)
• You were forced off Zepbound by an insurance formulary edit (CVS Caremark July 2025 swap, BMI clawback, or denial) and want to understand the realistic alternative paths plus the formulary-exception appeal — see our Zepbound alternatives 2026: Caremark-displaced edition for the rank-ordered playbook.

Pick Foundayo if...

• You have commercial insurance and qualify for the $25/month savings card
• You hate needles and would prefer a daily pill
• You travel frequently and don't want to manage cold chain logistics
• You expect to need short-notice surgery or a procedure (Foundayo's 29-49 hour half-life means a much shorter ASA hold timeline than the injectables)
• You want a drug you can take any time of day with or without food — no empty-stomach rule, no water restrictions, no 30-minute fast before eating
• An ~11% expected weight loss is meaningful enough for your goals (most patients with BMI ≥35 will say yes)

What this comparison is NOT

This is a head-to-head summary, not a clinical recommendation. The right drug for any individual patient depends on their full medical history, comorbidities, insurance situation, lifestyle, and tolerance for the GI side effects in the first 2-4 months. Discuss the choice with a qualified prescriber. This article is informational only.

This article also is not a switching guide. If you are already on one of these drugs and considering a change to another, the FDA labels do not contain a dose-equivalence conversion table — switching is a prescriber decision. For the specific Foundayo ↔ Zepbound switch question (verbatim §2 dose ranges side-by-side, the cross-trial efficacy comparison, the practical re-titration logic, and the oral-contraceptive label-asymmetry that affects patients of reproductive potential), see our companion Foundayo ↔ Zepbound switch dose-equivalence guide. For broader cross-class switching (semaglutide ↔ tirzepatide, brand ↔ compounded, etc.), see the switching between GLP-1 medications guide.

Bottom line

• All three drugs are FDA-approved for chronic weight management with BMI ≥30 (or ≥27 with comorbidity).
• Effect size: Zepbound > Wegovy > Foundayo on the published mean trial data.
• Cost (commercial insurance): Foundayo $25 savings card << Wegovy/Zepbound copays.
• Cost (cash pay): Foundayo $149 < Wegovy NovoCare $199 all-dose < Zepbound LillyDirect $299-$449.
• Delivery: Foundayo daily pill (no needles, no refrigeration); Wegovy and Zepbound weekly subcutaneous injections.
• Unique features: Wegovy has a labeled cardiovascular benefit, Zepbound has a labeled OSA indication, Foundayo has the lowest cost and the easiest logistics.

Related research and tools

• What is the best GLP-1 for weight loss? Ranked by FDA evidence (2026) — the cross-class ranking that places this Foundayo / Wegovy / Zepbound three-way comparison in the broader four-drug + retatrutide-pipeline context, with the criterion-by-criterion decision framework (magnitude, cardiovascular outcomes, oral route, cost).
• Compounded tirzepatide vs compounded semaglutide — if you are considering the compounded route instead of brand-name Wegovy or Zepbound: molecule differences, fridge life (28–90 day pharmacy BUD), regulatory status post-Feb 2025, and the SURMOUNT-5 efficacy comparison with cross-trial caveat
• Where to inject tirzepatide (Zepbound / Mounjaro) — the 3 FDA-approved injection sites, rotation rules to prevent lipohypertrophy, and step-by-step pen vs vial technique
• Weight loss injections guide 2026 — every FDA-approved injectable (Wegovy, Zepbound, Saxenda), head-to-head SURMOUNT-5 data, verbatim FDA safety warnings, and verified cash-pay pricing
• Rybelsus alternatives: when oral semaglutide isn't working — switching to Foundayo, Wegovy, or Zepbound when the T2D-only oral GLP-1 isn't producing the weight loss patients wanted
• GLP-1 Drug Decision Quiz — 4-step quiz: BMI + comorbidity + form preference → FDA-approved drug match with cited trial evidence
• Foundayo (orforglipron) approval deep-dive — the full ATTAIN-1 trial review and approval narrative
• How to take Foundayo — daily protocol, food restrictions, missed dose rules
• How to get a GLP-1 prescription in 2026 — buyer funnel for all four paths
• Wegovy vs Ozempic vs Zepbound vs Mounjaro brand name cheat sheet
• Tirzepatide vs semaglutide head-to-head — the SURPASS-2 direct comparison
• GLP-1 savings calculator 2026 — compare 10 access paths over 1, 5, and 10 years
• GLP-1 weight loss calculator — STEP-1 / SURMOUNT-1 / ATTAIN-1 trial-data-backed predictor
• GLP-1 BMI calculator — eligibility check + outcome overlay for all three drugs
• GLP-1 drug interaction checker
• Tennessee Medicaid (TennCare) GLP-1 coverage (2026): Wegovy + Zepbound both Preferred — TennCare is among the most favorable state Medicaid programs for accessing both Wegovy and Zepbound with verifiable Preferred-PDL status, FDA-label-aligned BMI criteria, and a 1-year initial PA window. Foundayo (orforglipron) does not bill insurance and is not a TennCare pathway.
• When to increase your Mounjaro dose for weight loss (titration decision guide) — if you are on Zepbound or off-label Mounjaro and wondering when to move up the dose ladder: FDA Section 2 verbatim, SURMOUNT-1 protocol, and the 4-condition framework

Important disclaimer. This article is educational and does not constitute medical advice. The choice between Foundayo, Wegovy, and Zepbound should be made with a prescribing clinician who knows your medical history. Pricing is current as of April 2026 and is updated as the manufacturer programs change. Effect size data is from the cited registration trials and reflects population means; individual outcomes vary substantially.